PE20070208A1 - Anticoncepcion oral con trimegestona - Google Patents

Anticoncepcion oral con trimegestona

Info

Publication number
PE20070208A1
PE20070208A1 PE2006000869A PE2006000869A PE20070208A1 PE 20070208 A1 PE20070208 A1 PE 20070208A1 PE 2006000869 A PE2006000869 A PE 2006000869A PE 2006000869 A PE2006000869 A PE 2006000869A PE 20070208 A1 PE20070208 A1 PE 20070208A1
Authority
PE
Peru
Prior art keywords
combination
trimegestone
composition
ethinylestradiol
refers
Prior art date
Application number
PE2006000869A
Other languages
English (en)
Inventor
Oliver Gloger
Heinrich Kugelmann
Mario Popova
Tamara Pfaff
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37575731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20070208A1 publication Critical patent/PE20070208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA PREFERIBLEMENTE SOLIDA, QUE COMPRENDE TRIMEGESTONA (17ß-[(S)-2-HIDROXIPROPANOIL]-17*-METIL-ESTRA-4,9-DIEN-3-ONA) EN UNA CANTIDAD SUPERIOR A 500ug Y OPCIONALMENTE EN COMBINACION CON AL MENOS UN ESTROGENO TAL COMO ETINILESTRADIOL O EN COMBINACION CON DOS ESTROGENOS TAL COMO ETINILESTRADIOL Y ESTRADIOL CORRESPONDE A UNA DOSIS EQUIVALENTE DE 5,0 A 55 ug DE ETINILESTRADIOL, Y/O OPCIONALMENTE EN COMBINACION CON AL MENOS UN PROGESTAGENO ADICIONAL Y/O CON AL MENOS UNA SUSTANCIA ADICIONAL TAL COMO ACIDO FOLICO O ACIDO FOLINICO, ENTRE OTROS. DICHA COMPOSICION ES DE ADMINISTRACION ORAL BAJO LA FORMA DE COMPRIMIDOS RECUBIERTOS DE PELICULA, GRAGEAS Y CAPSULAS. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE DICHA COMPOSICION LA CUAL ES UTIL PARA LA ANTICONCEPCION
PE2006000869A 2005-07-20 2006-07-19 Anticoncepcion oral con trimegestona PE20070208A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005034498A DE102005034498A1 (de) 2005-07-20 2005-07-20 Orale Kontrazeption mit Trimegeston
US11/348,545 US20070021396A1 (en) 2005-07-20 2006-02-06 Oral contraception with trimegestone

Publications (1)

Publication Number Publication Date
PE20070208A1 true PE20070208A1 (es) 2007-05-06

Family

ID=37575731

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000869A PE20070208A1 (es) 2005-07-20 2006-07-19 Anticoncepcion oral con trimegestona

Country Status (13)

Country Link
US (3) US20070021396A1 (es)
JP (1) JP2009501747A (es)
CN (1) CN101267827A (es)
BR (1) BRPI0614672A2 (es)
DE (1) DE102005034498A1 (es)
EC (1) ECSP088123A (es)
IL (1) IL188751A0 (es)
MX (1) MX2008000844A (es)
NO (1) NO20080824L (es)
NZ (1) NZ565829A (es)
PE (1) PE20070208A1 (es)
RU (1) RU2008105834A (es)
ZA (1) ZA200800373B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP2027855A1 (de) * 2007-08-24 2009-02-25 Bayer Schering Pharma AG Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
DE102007047608A1 (de) * 2007-10-04 2009-04-09 Grünenthal GmbH 19-nor-Progesterone zur Kontrazeption
US9271991B2 (en) 2010-10-27 2016-03-01 Dignity Health Trimegestone (TMG) for treatment of preterm birth
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP6386711B2 (ja) * 2013-10-01 2018-09-05 任天堂株式会社 情報処理システム、サーバ装置、サーバプログラム及び情報処理方法
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP6759478B2 (ja) * 2019-02-13 2020-09-23 富士製薬工業株式会社 経口固形組成物、その製造方法、及びその製造方法によって得られた経口用錠剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430953A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives 3,20-dioxo 4,9-diene 21-hydroxyle, leur procede de preparation et leur application comme medicaments
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
ATE249222T1 (de) * 1996-07-26 2003-09-15 Wyeth Corp Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
EP0917466B1 (en) * 1996-07-26 2004-10-06 Wyeth Oral contraceptive
KR100518102B1 (ko) * 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
JP2002512185A (ja) * 1998-04-17 2002-04-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 葉酸を含有する製薬学的組成物並びに関連する方法及び送達系
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
US20040063721A1 (en) * 2002-08-15 2004-04-01 Wyeth Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction
ATE409041T1 (de) * 2003-03-28 2008-10-15 Pantarhei Bioscience Bv Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind
GB2402745B (en) * 2003-06-10 2005-08-24 Activeem Ltd Electromagnetic surveying for hydrocarbon reservoirs
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption

Also Published As

Publication number Publication date
DE102005034498A1 (de) 2007-01-25
RU2008105834A (ru) 2009-08-27
ZA200800373B (en) 2009-08-26
NZ565829A (en) 2012-01-12
JP2009501747A (ja) 2009-01-22
US20120028936A1 (en) 2012-02-02
US20070021396A1 (en) 2007-01-25
IL188751A0 (en) 2008-12-29
BRPI0614672A2 (pt) 2012-12-04
MX2008000844A (es) 2008-03-18
NO20080824L (no) 2008-04-18
CN101267827A (zh) 2008-09-17
US20100279989A1 (en) 2010-11-04
ECSP088123A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
PE20070208A1 (es) Anticoncepcion oral con trimegestona
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
JP2009512658A5 (es)
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
PE20070344A1 (es) Regimenes para la administracion de las unidades de dosificacion de anticonceptivos monofasicos orales
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
SI1526856T1 (sl) Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
TW200612962A (en) Estriol and estetrol prodrugs
CL2011000283A1 (es) Preparado combinado polifasico que comprende 4 fases con unidades de dosis que contienen primera : <3 mg de estradiol (et), segunda: unas con <2 mg de et y 2 mg de dienogest (dg) y otras con <2 mg de et y 3 mg de dg, tercera: <1 mg de et y cuarta: placebo; util para la anticoncepcion oral y tratar para la hemorragia uterina disfuncional.
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
DOP2006000035A (es) Preparación farmaceútica para la anticoncepción oral
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
UA97960C2 (ru) ПРИМЕНЕНИЕ ЭСТРАДИОЛА ВАЛЕРАТА ИЛИ 17β-ЭСТРАДИОЛА В КОМБИНАЦИИ С ДИЕНОГЕСТОМ ДЛЯ ПЕРОРАЛЬНОГО ЛЕЧЕНИЯ ДЛЯ ПОДДЕРЖАНИЯ И/ИЛИ ПОВЫШЕНИЯ ПОЛОВОГО ВЛЕЧЕНИЯ У ОСОБИ ЖЕНСКОГО ПОЛА
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral

Legal Events

Date Code Title Description
FC Refusal